First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC

Схожие документы

• Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
  по: Liam, Chong-Kin
  Опубликовано: (2017)
• Osimertinib for EGFR-mutant non-small cell lung cancer: place in therapy and future perspectives
  по: Ricciuti, Biagio
  Опубликовано: (2019)
• Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
  по: Denis, Marc G, et al.
  Опубликовано: (2020)
• Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset
  по: Ohe, Yuichiro, et al.
  Опубликовано: (2018)
• First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
  по: Jeong, Byeong-Ho, et al.
  Опубликовано: (2018)